生物技术通报2016，Vol.32Issue(8)：34-40,7.DOI:10.13560/j.cnki.biotech.bull.1985.2016.08.007
大肠杆菌中生物药物的生产现状及展望
The Current Status and Future Perspectives of Production of Biopharmaceuticals in Escherichia coli
蔡东梅 1龚国利1
作者信息
- 1. 陕西科技大学食品与生物工程学院，西安 710021
- 折叠
摘要
Abstract
Escherichia coli is the most preferred microorganism to express heterologous protein for therapeutic use,as around 30%of the approved therapeutic proteins are currently being produced using it as a host. Due to its rapid growth,high yield,cost-effectiveness, and easy scale-up process,E. coli is chosen as an expression host in biotech industry for large-scale production of proteins. However,codon preference in E. coli and absences of post-translational modifications,such as glycosylation,phosphorylation and proteolytic processing limit its use for the production of slightly complex recombinant biopharmaceuticals. On purpose of helping E. coli to produce more complex and also glycosylated proteins for therapeutic use,this review summarizes the several novel technological advancements meeting the requirements of biotech industry,mainly focusing on the process of E. coli glycosylating heterologous proteins and expressing complex proteins including full-length glycosylated antibodies via those advancements. Further potential problems and prospects of futures researches are also discussed.关键词
大肠杆菌/生物制药学/密码子偏好性/分子伴侣Key words
Escherichia coli/biopharmaceuticals/codon preference/molecular chaperones引用本文复制引用
蔡东梅,龚国利..大肠杆菌中生物药物的生产现状及展望[J].生物技术通报,2016,32(8):34-40,7.
